Skip to content
CFPS Research Archives

Risuteganib

Human clinical Healing & Recovery 3 sources

Risuteganib (also known as Luminate) is a synthetic peptide that functions as a broad-spectrum integrin inhibitor. It is primarily researched for its potential to treat retinal diseases such as diabetic macular edema and dry age-related macular degeneration by reducing oxidative stress and regulating angiogenesis.

01Dosing reference

Amount
1.0 mg per dose (in clinical trials)
Frequency
Administered as a single or series of intravitreal injections depending on the trial protocol
Cycle
Typically evaluated over 12 to 24 weeks in clinical settings
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

Integrin Binding

Risuteganib binds to multiple integrin receptors, including αVβ3, αVβ5, α5β1, and αMβ2, which are implicated in angiogenesis and inflammation.

02

Oxidative Stress Reduction

By inhibiting these integrins, the peptide downregulates pathways that lead to oxidative stress and abnormal blood vessel growth in the retina.

03

Retinal Protection

This dual action helps protect retinal pigment epithelium (RPE) cells from damage and reduces vascular leakage, potentially restoring visual function.

03Human evidence

Improved visual acuity in dry AMD

A Phase 2 clinical trial demonstrated that patients with intermediate dry age-related macular degeneration experienced significant improvements in best-corrected visual acuity (BCVA) following treatment.

Reduction of macular edema

Phase 2 studies in patients with diabetic macular edema (DME) showed that the compound could reduce central retinal thickness and improve vision, comparable to some existing therapies.

04Preclinical evidence

Protection of RPE cells

In vitro studies using human retinal pigment epithelium cells showed that Risuteganib protected against hydroquinone-induced oxidative stress and cell death.

Inhibition of neovascularization

Animal models of choroidal neovascularization demonstrated that the peptide significantly reduced the size of vascular lesions and prevented abnormal blood vessel growth.

05What is known vs. unknown

Reasonably established
  • Functions as a broad-spectrum integrin inhibitor rather than targeting a single pathway.
  • Investigated primarily for ophthalmic conditions such as dry AMD and DME.
  • Administered via intravitreal injection in clinical settings.
  • Shows potential in restoring the function of retinal pigment epithelium cells.
Unknowns & limits
  • Long-term efficacy and safety beyond Phase 2 clinical trials are not yet fully established.
  • The optimal dosing frequency for managing chronic retinal conditions remains under investigation.
  • Its effectiveness compared to newer, longer-acting anti-VEGF agents is still being evaluated.

06Safety & regulatory context

Regulatory statusIn clinical trials, Risuteganib has been administered via intravitreal injection and has generally been well-tolerated, with adverse events mostly related to the injection procedure itself rather than systemic toxicity. It is currently an investigational drug and has not been approved by the FDA for the treatment of any condition. Research is ongoing to fully establish its safety profile for long-term use in ophthalmic diseases.

07Compared with Ranibizumab (Anti-VEGF)

Risuteganib vs. Ranibizumab (Anti-VEGF)
Key difference
Risuteganib targets multiple integrins to address both oxidative stress and angiogenesis, whereas Ranibizumab specifically inhibits vascular endothelial growth factor (VEGF).
When researchers discuss each
Researchers discuss Ranibizumab as a standard-of-care for wet AMD and DME, while Risuteganib is explored as a novel mechanism that may benefit dry AMD or patients unresponsive to anti-VEGF therapy.

08Glossary

Integrin
A type of cell surface receptor that helps cells bind to the extracellular matrix and regulates cellular signals related to growth and survival.
Angiogenesis
The physiological process through which new blood vessels form from pre-existing vessels, which can be harmful in certain eye diseases.
Retinal Pigment Epithelium (RPE)
A layer of cells in the eye that nourishes and protects the visual cells of the retina.
Intravitreal Injection
A procedure to place a medication directly into the space in the back of the eye called the vitreous cavity.

09Knowledge check

Q1What is the primary mechanism of action for Risuteganib?
Q2How is Risuteganib primarily administered in clinical trials for eye diseases?
Q3Which of the following best reflects a documented limitation of the current clinical evidence for Risuteganib?
Q4According to the dossier, how is Risuteganib most clearly distinguished from Ranibizumab in research discussions?
Q5Which statement accurately reflects the safety or regulatory context for Risuteganib as reported in the dossier?

10Sources

More in Healing & Recovery

See all

BPC-157

Healing & Recovery
Early human

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

250-500 mcg

TB-500 (Thymosin Beta-4)

Healing & Recovery
Early human

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. Research indicates it plays a crucial role in tissue repair, wound healing, and reducing inflammation by upregulating actin, a vital protein for cell structure and movement.

2.0 - 2.5 mg per injection

KPV

Healing & Recovery
Early human

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Research highlights its potent anti-inflammatory and antimicrobial properties, making it a promising candidate for conditions like inflammatory bowel disease, skin disorders, and wound healing.

200-500 mcg/day
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.